While the impact of the IRA on the pharmaceutical industry cannot yet be fully determined, it is likely to be significant.
All entries for: Cardiology
February 24, 2026
BridgeBio Pharma, Inc
Neutral Outlook
Palo Alto, CA
501-1,000 employees
Although the effects of the IRA on our business and the healthcare industry in general are not yet known, we are taking into consideration the potential impact of the IRA on our development and commercialization activities.
Disease Area: Cardiology, Endocrinology, Metabolic Diseases, Neurological Diseases, Rare Diseases
Drug Type: Small Molecule
February 23, 2026
Bristol Myers Squibb
Layoffs
Lawrence Township, NJ
10,000+ employees
Bristol Myers Squibb plans to reduce its Lawrenceville, New Jersey headcount by 247 employees, with layoffs running from May 21 through the end of the year, continuing a series of workforce reductions at its New Jersey operations over the past year.
Disease Area: Cardiology, Hematology, Immune Diseases, Multiple, Oncology
Drug Type: Biologic, Small Molecule
February 12, 2026
Alnylam Pharmaceuticals, Inc.
Neutral Outlook
Cambridge, MA
1,001-5,000 employees
Manufacturers that fail to comply with the IRA may be subject to various penalties, including civil monetary penalties or a potential excise tax. The impact of the IRA on the pharmaceutical industry is significant and ongoing.
Disease Area: Cardiology, Metabolic Diseases, Neurological Diseases, Rare Diseases
Drug Type: Biologic
February 12, 2026
Eli Lilly & Co
Negative Outlook
Indianapolis, IN
10,000+ employees
The IRA has, and will continue to, meaningfully influence our business strategies and those of our competitors. In particular, the nine-year timeline to set prices for medicines approved under a New Drug Application reduces the attractiveness of investment in small molecule innovation. The IRA can cause changes to development approach and timing and investments at-risk. The full impact of the IRA on our business and the pharmaceutical industry, including the implications to us of a competitor’s product being selected for price setting, remains uncertain.
Disease Area: Cardiology, Chronic Disease, Immune Diseases, Metabolic Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
February 11, 2026
Bristol Myers Squibb Co
Negative Outlook
Princeton, NJ
10,000+ employees
We continue to evaluate the impact of the IRA on our results of operations, and it is possible that these changes may result in a material impact on our business and results of operations.
Disease Area: Cardiology, Hematology, Immune Diseases, Multiple, Oncology
Drug Type: Biologic, Small Molecule
February 9, 2026
Genentech
Layoffs
South San Francisco, CA
10,000+ employees
A California WARN notice revealed that 141 employees were laid off across Genentech’s operations, with the terminations taking effect in August 2025. A company spokesperson attributed the delayed posting to a system glitch.
Disease Area: Cardiology, Hematology, Immune Diseases, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
November 25, 2025
Novartis
Layoffs
Basel, Baselstadt
10,000+ employees
Novartis will cut 550 full-time jobs at a facility in Switzerland by the end of 2027. The cuts come as the pharma company is ending production of tablets, capsules, and sterile medicine packaging at a plant in Stein, Switzerland.
Disease Area: Cardiology, Hematology, Immune Diseases, Multiple, Oncology
Drug Type: Biologic, Small Molecule